TWI562778B - - Google Patents

Info

Publication number
TWI562778B
TWI562778B TW101127773A TW101127773A TWI562778B TW I562778 B TWI562778 B TW I562778B TW 101127773 A TW101127773 A TW 101127773A TW 101127773 A TW101127773 A TW 101127773A TW I562778 B TWI562778 B TW I562778B
Authority
TW
Taiwan
Application number
TW101127773A
Other versions
TW201321003A (zh
Inventor
Toshiya Kanaji
Kazuhiro Fuchibe
Masaya Takahashi
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of TW201321003A publication Critical patent/TW201321003A/zh
Application granted granted Critical
Publication of TWI562778B publication Critical patent/TWI562778B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
TW101127773A 2011-08-02 2012-08-01 左心室擴張機能改善劑 TW201321003A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011169389 2011-08-02

Publications (2)

Publication Number Publication Date
TW201321003A TW201321003A (zh) 2013-06-01
TWI562778B true TWI562778B (zh) 2016-12-21

Family

ID=47629356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101127773A TW201321003A (zh) 2011-08-02 2012-08-01 左心室擴張機能改善劑

Country Status (16)

Country Link
US (1) US9682065B2 (zh)
EP (1) EP2740475A4 (zh)
JP (1) JP6052175B2 (zh)
KR (1) KR20140056250A (zh)
CN (1) CN103717219B (zh)
AU (1) AU2012290987B2 (zh)
BR (1) BR112014002377A2 (zh)
CA (1) CA2842906A1 (zh)
HK (1) HK1197194A1 (zh)
IL (1) IL230686A0 (zh)
MX (1) MX2014000971A (zh)
RU (1) RU2627842C2 (zh)
SG (1) SG2014007603A (zh)
TW (1) TW201321003A (zh)
WO (1) WO2013018837A1 (zh)
ZA (1) ZA201401487B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106748951B (zh) 2012-07-19 2020-07-24 开曼化学股份有限公司 作为在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
WO2017136775A1 (en) * 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
ES2954717T3 (es) 2017-05-22 2023-11-23 Ono Pharmaceutical Co Antagonista de EP4
RU2762989C1 (ru) * 2020-09-28 2021-12-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ лечения собак, больных дилатационной кардиомиопатией, осложненной застойной сердечной недостаточностью

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041729A1 (en) * 2000-01-31 2001-11-15 Paralkar Vishwas M. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
EP1782829A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist
CN101921220A (zh) * 2001-07-23 2010-12-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (zh) 1970-06-10 1975-02-04
JPS5231404B1 (zh) 1971-04-28 1977-08-15
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US5938890A (en) 1998-06-27 1999-08-17 Automatic Manufacturing Systems, Inc. Adhesive components peel and apply apparatus and method
EE200200355A (et) 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 retseptori selektiivsed agonistid osteoporoosi raviks
AU2001278771A1 (en) 2000-08-22 2002-03-04 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
CA2451393C (en) 2001-07-16 2011-01-04 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
EP1409455B1 (en) 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists
JP4888775B2 (ja) 2004-08-10 2012-02-29 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
JP2006321737A (ja) 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041729A1 (en) * 2000-01-31 2001-11-15 Paralkar Vishwas M. Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
CN101921220A (zh) * 2001-07-23 2010-12-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
EP1782829A1 (en) * 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist

Also Published As

Publication number Publication date
KR20140056250A (ko) 2014-05-09
HK1197194A1 (zh) 2015-01-09
JPWO2013018837A1 (ja) 2015-03-05
RU2627842C2 (ru) 2017-08-14
EP2740475A4 (en) 2015-02-25
CN103717219A (zh) 2014-04-09
AU2012290987A1 (en) 2014-02-20
IL230686A0 (en) 2014-03-31
US9682065B2 (en) 2017-06-20
TW201321003A (zh) 2013-06-01
RU2014107904A (ru) 2015-09-10
MX2014000971A (es) 2014-02-27
AU2012290987B2 (en) 2017-04-20
JP6052175B2 (ja) 2016-12-27
CA2842906A1 (en) 2013-02-07
SG2014007603A (en) 2014-03-28
BR112014002377A2 (pt) 2017-02-21
ZA201401487B (en) 2015-12-23
US20140179606A1 (en) 2014-06-26
NZ620451A (en) 2015-11-27
CN103717219B (zh) 2017-02-15
EP2740475A1 (en) 2014-06-11
WO2013018837A1 (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
BR112013022641A2 (zh)
AP3853A (zh)
BR112013031251A2 (zh)
BR112013027245A2 (zh)
BR112013026905A2 (zh)
BR112013023185A2 (zh)
BR112013022995A2 (zh)
BR112013026744A2 (zh)
BR112013023927A2 (zh)
BR112013027830A2 (zh)
BR112013028733A2 (zh)
BR112013027121A2 (zh)
BR112013027452A2 (zh)
AP2016009466A0 (zh)
BR112013031556A2 (zh)
BR112013026790A2 (zh)
BR112013032380A2 (zh)
BR112013032377A2 (zh)
BR112013032366A2 (zh)
BR112013018949A2 (zh)
BR112013026895A2 (zh)
BR112013027761A2 (zh)
BR112013021637A2 (zh)
BR112013027836A2 (zh)
BR112013023266A2 (zh)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees